Holen Sie sich die Stockscreener-App
2.1218
2.22%
-0.0482
Handel nachbörslich:
2.12
-0.0018
-0.08%
Schlusskurs vom Vortag:
$2.17
Offen:
$2.08
24-Stunden-Volumen:
2,720
Relative Volume:
0.17
Marktkapitalisierung:
$23.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-6.9522
EPS:
-0.3052
Netto-Cashflow:
$-2.23M
1W Leistung:
-9.32%
1M Leistung:
-9.32%
6M Leistung:
-39.38%
1J Leistung:
+4.53%
1-Tages-Spanne:
$2.08
$2.1218
1-Wochen-Bereich:
$2.0701
$2.34
52-Wochen-Spanne:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
Firmenname
Cytomed Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GDTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
2.1218 | 23.66M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus
CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened - Defense World
CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India - Yahoo Finance
CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India - Yahoo Finance
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga
CytoMed Therapeutics Limited Signs Business & Research Collaboration Agreement with Sunact Cancer Institute Private Limited to Advance Use of Allogeneic Off-The-Shelf Gamma Delta T Cells for Treatment of Solid Cancers in Proposed Phase 2 Clinical Tr - Marketscreener.com
CytoMed and SunAct partner for cancer immunotherapy trials - Investing.com
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - Marketscreener.com
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - Simply Wall St
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Yahoo Finance
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Emergence of Cell and Gene Therapy Community in Singapore - BSA bureau
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration | Value Investing NewsInvestor powered stock market news - Financial Content
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
Singapore-China collaboration to explore allogeneic gamma delta T cell technology for cancer treatment - BioSpectrum Asia
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
CytoMed Expands Research Collaboration into China After Entering Into MOU - StreetInsider
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - PR Newswire
CytoMed Therapeutics Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Investing.com South Africa
Singapore's CytoMed Therapeutics announces collaboration with MD Anderson Cancer Center in US - BioSpectrum Asia
CytoMed and MD Anderson partner to use gdTc for cancer treatment - Pharmaceutical Technology
CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - PR Newswire
Peter Choo-backed biomed firm CytoMed lists on Nasdaq - The Edge Singapore
GDTCCytoMed Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering - PR Newswire
IPO Update: CytoMed Therapeutics Aims For $11 Million U.S. IPO (Pending:GDTC) - Seeking Alpha
CytoMed Therapeutics (NASDAQ:GDTC) Stock Quotes, Forecast and News Summary - Benzinga
Malaysia-Singapore Collaborates In The Field Of Clinical Research - BusinessToday Malaysia
Compulsory vaccination: MOH prepared to hear views from all - thesun.my
Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):